Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The expansion makes Exothera one of the largest viral vector facilities in Europe
Successful proposals will secure fully funded postdoctoral research positions
Subscribe To Our Newsletter & Stay Updated
